Clinical Trials Browser

Phase 3 × durvalumab × 30 days × Clear all

Carcinoma, Non-Small-Cell Lung

Anatomic Stage II Breast Cancer AJCC v8

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Biliary Tract Neoplasms

Non-Muscle Invasive Bladder Neoplasms

Carcinoma, Carcinoma, Renal Cell, Neoplasm Metastasis

Small Cell Lung Carcinoma

Small Cell Lung Carcinoma

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Parkinson Disease 4, Autosomal Dominant Lewy Body, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Biliary Tract Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Esophageal Squamous Cell Carcinoma

Carcinoma, Non-Small-Cell Lung, Lung Neoplasms

Carcinoma, Non-Small-Cell Lung

Biliary Tract Neoplasms, Gallbladder Neoplasms, Cholangiocarcinoma

Oropharyngeal Neoplasms

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Carcinoma, Non-Small-Cell Lung

Lung Neoplasms

Carcinoma, Hepatocellular

Clinical Trials

Comparing Photon Therapy To Proton Therapy To Treat Patients With Lung Cancer

Adding an Immunotherapy Drug, MEDI4736 (Durvalumab), to the Usual Chemotherapy Treatment (Paclitaxel, Cyclophosphamide, and Doxorubicin) for Stage II-III Breast Cancer

Immunotherapy After Surgery for People Who Have No Remaining Cancer Cells After Standard Treatment for Early-Stage Non-Small Cell Lung Cancer, INSIGHT Trial

TOPAZ-1

PATAPSCO

SAMETA

DeLLphi-312

ALBORAN

ROSY-D

SUNRAY-02

PACIFIC-8

PACIFIC-9

MK-7339-012

DESTINY-BTC01

A Study to Evaluate Pumitamig Versus Durvalumab Following Concurrent Chemoradiation Therapy in Participants With Unresectable Stage III Non-small Cell Lung Cancer (NSCLC) (ROSETTA Lung-201)

PACIFIC-5

KUNLUN

CLEAR

MYSTIC

Efficacy and Safety of Zanidatamab With Standard-of-care Therapy Against Standard-of-care Therapy for Advanced HER2-positive Biliary Tract Cancer

CompARE

HORIZON 1

Beamion LUNG-3: Adjuvant Zongertinib vs Standard Treatment in People With Completely Resected Stage II-IIIB NSCLC Harboring Activating HER2 TKD Mutations

Personalized Escalation of Consolidation Treatment Following Chemoradiotherapy and Immunotherapy in Stage III NSCLC in Stage III NSCLC

Testing the Addition of High Dose, Targeted Radiation to the Usual Treatment for Locally-Advanced Inoperable Non-Small Cell Lung Cancer

Testing Immunotherapy With or Without Stereotactic Body Radiation Therapy in Patients With Advanced Liver Cancer, HELIO-RT Trial